Results of multicenter international trail for pediatric primary mediastinal B-cell lymphoma treated according to protocols B-NHL-M-10 and DA-EPOCH-R

Y. G. Abugova; Абугова Ю. Г.; N. V. Miakova; Мякова Н. В.; D. S. Abramov; Абрамов Д. С.; Y. Y. Diakonova; Дьяконова Ю. Ю.; V. V. Fominih; Фоминых В. В.; D. A. Evstratov; Евстратов Д. А.; L. A. Potapenko; Потапенко Л. А.; A. Е. Rudneva; Руднева А. Е.; E. Е. Kurnikova; Курникова Е. Е.; Y. N. Likar; Ликарь Ю. Н.; E. V. Samochatova; Самочатова Е. В.

doi:10.24287/1726-1708-2019-18-1-43-48

Results of multicenter international trail for pediatric primary mediastinal B-cell lymphoma treated according to protocols B-NHL-M-10 and DA-EPOCH-R

Authors: Abugova Y.G.¹, Miakova N.V.¹, Abramov D.S.¹, Diakonova Y.Y.¹, Fominih V.V.¹, Evstratov D.A.¹, Potapenko L.A.¹, Rudneva A.Е.¹, Kurnikova E.Е.¹, Likar Y.N.¹, Samochatova E.V.¹
Affiliations:
1. Dmitriy Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology Ministry of Healthcare of Russian Federation
Issue: Vol 18, No 1 (2019)
Pages: 43-48
Section: ORIGINAL ARTICLES
Submitted: 21.04.2019
Accepted: 21.04.2019
Published: 21.04.2019
URL: https://hemoncim.com/jour/article/view/237
DOI: https://doi.org/10.24287/1726-1708-2019-18-1-43-48
ID: 237

Cite item

Full Text

Abstract
About the authors
References
Supplementary files
Statistics

Abstract

During last years dose-adjusted EPOCH chemotherapy has become the most common international fist-line regimen of treatment of primary mediastinal B-cell lymphoma ^МВ^). Our goal is to evaluate results of multicentre international trail of treatment for children with PMBCL according to B-NHL-М-Ю and with dose-adjusted EPOCH protocol. This study was supported by the Independent Ethical Committee of State Nature Research Institute and approved by the decision of the Academic Council. More than 20 clinics from Russian Federetion and republic of Belarus are involved in this reaserch. Since January 2011 to June 2017 246 patients with first diagnosed NHL were included in the study, 18 of them had PMBCL (7.3%). Results: 10 patients (55.5%) were treated according to BNHL protocol, 8 (44.4%) patients received Dа-EPOCH-R protocol. With median follow-up of 3-year, EFS for patients with treatment according to B-NHL-М-Ю protocol was 70% for other with Dа-EPOCH-R - 67%.